Latest Commercialisation News

Challenger Gold has secured a binding toll processing agreement to fast-track production at its Hualilan Gold Project in Argentina, while also reporting promising drilling results from its Colorado V project in Ecuador and completing a strategic capital raise.

Dreadnought Resources reports robust exploration results including high-grade gold at Mangaroon and niobium at Gifford Creek, alongside new joint ventures and asset sales that position the company for growth.

Pursuit Minerals has reported a remarkable 339% increase in lithium resources at its Rio Grande Sur project in Argentina, alongside plans to commence lithium carbonate production by Q1 2025. The company is also actively pursuing acquisitions and reviewing its gold assets amid tight cost controls.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Alexium International Group reports a 16% sales increase in Q2 FY25 despite ongoing mattress market softness, driven by strategic product diversification and supply chain improvements.

Accelerate Resources has secured a 70% stake in the Kanowna East Gold Project near Kalgoorlie and raised $1.35 million to accelerate exploration, while also identifying lithium-bearing spodumene at Mt Sholl East.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

Pure Resources Limited has made significant strides in its Reedy Creek Garnet Project, expanding the resource and delivering promising metallurgical test results that highlight the project's commercial potential.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

Cokal Limited has strengthened its position in Central Kalimantan through strategic partnerships with PT Petrindo and Cratus Group, securing US$20 million in funding to boost coal production and infrastructure development.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.